The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses

Antiviral Research

Volumn 93, Issue 1, 2012, Pages 144-153

  Wu, Wai Lan ^a   Lau, Siu Ying ^a   Chen, Yixin ^c   Wang, Genyan ^b   Mok, Bobo Wing Yee ^a   Wen, Xi ^a   Wang, Pui ^a   Song, Wenjun ^a   Lin, Tianwei ^c   Chan, Kwok Hung ^a   Yuen, Kwok Yung ^a   Chen, Honglin ^a,b  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHANTOU UNIVERSITY   (China)

^c XIAMEN UNIVERSITY   (China)

Author keywords

H1N1; H275Y; Influenza; Neuraminidase; Oseltamivir; Resistance

Indexed keywords

ANTISERUM; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; OSELTAMIVIR; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGENICITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLADISTICS; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; IN VIVO STUDY; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; SEASONAL INFLUENZA; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ADULT; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; PHYLOGENY; VIRAL PROTEINS; YOUNG ADULT;

FLU VACCINE; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 84355165239     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.11.006     Document Type: Article

References (50)

1. Bloom J.D., Gong L.I., Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010, 328:1272-1275.
2. Bouvier N.M., Lowen A.C., Palese P. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J. Virol. 2008, 82:10052-10058.
3. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366:1175-1181.
4. Bright R.A., Shay D.K., Shu B., Cox N.J., Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006, 295:891-894.
5. Carr J., Ives J., Kelly L., Lambkin R., Oxford J., Mendel D., Tai L., Roberts N. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002, 54:79-88.
6. Chen H., Smith G.J., Li K.S., Wang J., Fan X.H., Rayner J.M., Vijaykrishna D., Zhang J.X., Zhang L.J., Guo C.T., Cheung C.L., Xu K.M., Duan L., Huang K., Qin K., Leung Y.H., Wu W.L., Lu H.R., Chen Y., Xia N.S., Naipospos T.S., Yuen K.Y., Hassan S.S., Bahri S., Nguyen T.D., Webster R.G., Peiris J.S., Guan Y. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc. Natl. Acad. Sci. USA 2006, 103:2845-2850.
7. Chen H., Cheung C.L., Tai H., Zhao P., Chan J.F., Cheng V.C., Chan K.H., Yuen K.Y. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg. Infect. Dis. 2009, 15:1970-1972.
8. Cheng P.K., Leung T.W., Ho E.C., Leung P.C., Ng A.Y., Lai M.Y., Lim W.W. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg. Infect. Dis. 2009, 15:966-968.
9. Collins P.J., Haire L.F., Lin Y.P., Liu J., Russell R.J., Walker P.A., Skehel J.J., Martin S.R., Hay A.J., Gamblin S.J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008, 453:1258-1261.
10. Collins P.J., Haire L.F., Lin Y.P., Liu J., Russell R.J., Walker P.A., Martin S.R., Daniels R.S., Gregory V., Skehel J.J., Gamblin S.J., Hay A.J. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 2009, 27:6317-6323.
11. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St George K., Epperson S., Brammer L., Klimov A.I., Bresee J.S., Fry A.M. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
12. Dharan N.J., Gubareva L.V., Klimov A.I., Fiore A.E., Bresee J.S., Fry A.M. Antiviral treatment of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal Influenza A (H1N1) infection during the 2007-2008 influenza season in the United States. Clin. Infect. Dis. 2010, 50:621-622.
13. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., Sessions W.M., Xu X., Skepner E., Deyde V., Okomo-Adhiambo M., Gubareva L., Barnes J., Smith C.B., Emery S.L., Hillman M.J., Rivailler P., Smagala J., de Graaf M., Burke D.F., Fouchier R.A., Pappas C., Alpuche-Aranda C.M., Lopez-Gatell H., Olivera H., Lopez I., Myers C.A., Faix D., Blair P.J., Yu C., Keene K.M., Dotson P.D., Boxrud D., Sambol A.R., Abid S.H., St George K., Bannerman T., Moore A.L., Stringer D.J., Blevins P., Demmler-Harrison G.J., Ginsberg M., Kriner P., Waterman S., Smole S., Guevara H.F., Belongia E.A., Clark P.A., Beatrice S.T., Donis R., Katz J., Finelli L., Bridges C.B., Shaw M., Jernigan D.B., Uyeki T.M., Smith D.J., Klimov A.I., Cox N.J. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
14. Hamelin M.E., Baz M., Abed Y., Couture C., Joubert P., Beaulieu E., Bellerose N., Plante M., Mallett C., Schumer G., Kobinger G.P., Boivin G. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog. 2010, 6:e1001015.
15. Hauge S.H., Dudman S., Borgen K., Lackenby A., Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg. Infect. Dis. 2009, 15:155-162.
16. Herlocher M.L., Carr J., Ives J., Elias S., Truscon R., Roberts N., Monto A.S. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 2002, 54:99-111.
17. Herlocher M.L., Truscon R., Elias S., Yen H.L., Roberts N.A., Ohmit S.E., Monto A.S. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 2004, 190:1627-1630.
18. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA 2000, 97:6108-6113.
19. Hurt A.C., Holien J.K., Parker M., Kelso A., Barr I.G. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 2009, 83:10366-10373.
20. Hurt A.C., Holien J.K., Parker M.W., Barr I.G. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009, 69:2523-2531.
21. Hurt A.C., Nor'e S.S., McCaw J.M., Fryer H.R., Mosse J., McLean A.R., Barr I.G. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J. Virol. 2010, 84:9427-9438.
22. Hurt A.C., Deng Y.M., Ernest J., Caldwell N., Leang L., Iannello P., Komadina N., Shaw R., Smith D., Dwyer D.E., Tramontana A.R., Lin R.T., Freeman K., Kelso A., Barr I.G. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveill. 2011, 16.
23. Ives J.A., Carr J.A., Mendel D.B., Tai C.Y., Lambkin R., Kelly L., Oxford J.S., Hayden F.G., Roberts N.A. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002, 55:307-317.
24. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
25. Kiso M., Shinya K., Shimojima M., Takano R., Takahashi K., Katsura H., Kakugawa S., Le M.T., Yamashita M., Furuta Y., Ozawa M., Kawaoka Y. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog. 2010, 6.
26. Kohno S., Kida H., Mizuguchi M., Hirotsu N., Ishida T., Kadota J., Shimada J. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob. Agents Chemother. 2011, 55:2803-2812.
27. Lin Y.P., Gregory V., Collins P., Kloess J., Wharton S., Cattle N., Lackenby A., Daniels R., Hay A. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?. J. Virol. 2010, 84:6769-6781.
28. McKimm-Breschkin J.L. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res. 2000, 47:1-17.
29. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 2003, 47:2264-2272.
30. Meijer A., Jonges M., Abbink F., Ang W., van Beek J., Beersma M., Bloembergen P., Boucher C., Claas E., Donker G., van Gageldonk-Lafeber R., Isken L., de Jong A., Kroes A., Leenders S., van der Lubben M., Mascini E., Niesters B., Oosterheert J.J., Osterhaus A., Riesmeijer R., Riezebos-Brilman A., Schutten M., Sebens F., Stelma F., Swaan C., Timen A., Van't Veen A., van der Vries E., Te Wierik M., Koopmans M. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res. 2011.
31. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., Tashiro M., Webster R.G., Aymard M., Hayden F.G., Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3years of their use. Antimicrob. Agents Chemother. 2006, 50:2395-2402.
32. Moscona A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 2009, 360:953-956.
33. Oxford J. Oseltamivir in the management of influenza. Expert Opin. Pharmacother. 2005, 6:2493-2500.
34. Palese P., Wang T.T. Why do influenza virus subtypes die out? A hypothesis. MBio 2011, 2.
35. Potier M., Mameli L., Belisle M., Dallaire L., Melancon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 1979, 94:287-296.
36. Rameix-Welti M.A., Enouf V., Cuvelier F., Jeannin P., van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 2008, 4:e1000103.
37. Reddy D. Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir. J. Antimicrob. Chemother. 2010, 65(Suppl. 2):35-40.
38. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443:45-49.
39. Seibert C.W., Kaminski M., Philipp J., Rubbenstroth D., Albrecht R.A., Schwalm F., Stertz S., Medina R.A., Kochs G., Garcia-Sastre A., Staeheli P., Palese P. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J. Virol. 2010, 84:11219-11226.
40. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E.N., Wallis T.R., Klimov A.I., Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 2008, 52:3284-3292.
41. Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J. Infect. Chemother. 2011, 17:595-601.
42. Ujike M., Ejima M., Anraku A., Shimabukuro K., Obuchi M., Kishida N., Hong X., Takashita E., Fujisaki S., Yamashita K., Horikawa H., Kato Y., Oguchi A., Fujita N., Tashiro M., Odagiri T. Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. Emerg. Infect. Dis. 2011, 17:470-479.
43. Wagner R., Matrosovich M., Klenk H.D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 2002, 12:159-166.
44. Wang P., Song W., Mok B.W., Zhao P., Qin K., Lai A., Smith G.J., Zhang J., Lin T., Guan Y., Chen H. Nuclear factor 90 negatively regulates influenza virus replication by interacting with viral nucleoprotein. J. Virol. 2009, 83:7850-7861.
45. Weinstock D.M., Zuccotti G. The evolution of influenza resistance and treatment. JAMA 2009, 301:1066-1069.
46. World Health Organization, 2002. WHO Manual on Animal Influenza Diagnosis and Surveillance. World Health Organization.
47. Wu W.L., Chen Y., Wang P., Song W., Lau S.Y., Rayner J.M., Smith G.J., Webster R.G., Peiris J.S., Lin T., Xia N., Guan Y., Chen H. Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J. Virol. 2008, 82:1798-1807.
48. Yen H.L., Herlocher L.M., Hoffmann E., Matrosovich M.N., Monto A.S., Webster R.G., Govorkova E.A. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 2005, 49:4075-4084.
49. Yen H.L., Hoffmann E., Taylor G., Scholtissek C., Monto A.S., Webster R.G., Govorkova E.A. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol. 2006, 80:8787-8795.
50. Zambon M., Hayden F.G. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 2001, 49:147-156.